DeLisa invited by the National Academies of Science, Engineering and Medicine to serve on a special committee to identify emerging and upcoming pharmaceutical technologies
Matt was recently invited by the National Academies of Science, Engineering and Medicine to serve on a committee to identify emerging and upcoming technologies that have the potential to advance pharmaceutical quality and modernize pharmaceutical manufacturing for products regulated by the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration. This includes small and large molecules up to monoclonal antibodies or therapeutic proteins.
The committee’s approach will include collection of information, workshops on innovation and on technical and regulatory hurdles with highlights captured in workshop proceedings, and expert analysis that culminates in a peer-reviewed consensus report. The report will describe promising innovation areas and insights on key regulatory and technical challenges that the FDA and the pharmaceutical industry will need to address to realize the benefits of the innovation.
For more project information, please visit: